In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Centessa Pharmaceuticals Nets $353M in Nasdaq IPO of ADSs

Executive Summary

Asset centric start-up Centessa Pharmaceuticals Ltd. netted $353Med its initial public offering of 19M American Depositary Shares (ADSs; each represents one ordinary share and includes full exercise of the overallotment) at $20 per ADS (the high end of its anticipated $18-20 range) on the Nasdaq Global Market. It originally planned to offer 15M shares. Following the close of the IPO, the company changed its name to Centessa Pharmaceuticals plc

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies